<DOC>
	<DOCNO>NCT01807949</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy lumacaftor combination ivacaftor Week 24 participant age 12 year older cystic fibrosis ( CF ) homozygous F508del mutation CF transmembrane conductance regulator ( CFTR ) gene .</brief_summary>
	<brief_title>A Study Lumacaftor Combination With Ivacaftor Cystic Fibrosis Subjects Aged 12 Years Older Who Are Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , parallel-group multicenter study orally administer lumacaftor combination ivacaftor participant age 12 year old CF homozygous F508del-CFTR mutation . The study include Screening Period ( Day -28 Day -1 ) , Treatment Period ( Day 1 [ first dose study drug ] Week 24 ± 5 day ) , Safety Follow-up Visit ( 4 week ± 7 day Week 24 Visit ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF Homozygous F508del CFTR mutation Forced expiratory volume 1 second ( FEV1 ) great equal ( &gt; = ) 40 percent ( % ) less equal ( = &lt; ) 90 % predict normal age , sex , height Willing remain stable CF medication regimen Week 24 , applicable , Safety Follow Visit An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 4 week first dose study drug History solid organ hematological transplantation History alcohol drug abuse past year Ongoing prior participation investigational drug study ( include study investigate lumacaftor and/or ivacaftor ) within 30 day screen . Use strong inhibitor , moderate inducer , strong inducer Cytochrome P450 3A ( CYP3A ) within 14 day Day 1 dosing</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>